Jan. 24
Mark your calendar for these AHA 2017 eventsContinue your education throughout the year with AHA. From specialty conferences to Scientific Sessions 2017, AHA offers excellent education throughout the year. Five conferences will be held in 2017, each focusing on a unique specialty. Read More
Access science after Scientific SessionsWhether you missed a session or seek to review one you attended, you can gain access to every presentation delivered at Scientific Sessions 2016 with Sessions OnDemand™ Premium. This valuable video library gives you unlimited online and mobile access to Sessions presentations. Read More
Technology helping to advance treatment of patientsNew technology to improve professional approaches and patient outcomes was on display in sessions, demonstrations, competitions and even a lounge at Scientific Sessions 2016. Two different types of technology advances were highlighted in the HealthTech Competition and the Early Career Lounge. Read More
Networking expanded education opportunitiesFormal education presentations were a highlight of Scientific Sessions 2016, but interacting with researchers and other attendees in a variety of formats helped push learning opportunities to another level. Those opportunities ranged from meeting with renowned researchers to talking to poster presenters to networking with peers. Read More
Healthcare leaders look at the path of cardiovascular medicineScientific Sessions 2016 was a big event for the medical community, and it attracted a variety of renowned speakers. Two of those big speakers — Robert Califf, MD, Food and Drug Administration commissioner, and Victor Dzau, MD, president of the Institute of Medicine — looked at the role of cardiovascular medicine in the near future. Read More
Special programming targets specific groupsScientific Sessions 2016 featured programs that explored specialized information for increased learning for specific groups. These programs aimed at aiding cardiovascular nurses, exploring advances in resuscitation science and expanding general knowledge of genomics. Read More
Simulations a hit in Science & Technology HallThe Simulation Zone proved popular in its second-year appearance at Scientific Sessions 2016. It featured four regularly scheduled demonstrations that drew large crowds of participants. The simulations gave attendees an opportunity to test their knowledge, skills and critical thinking. Read More
Summits preview scientific research in four areasFull-day Frontiers in Science Summits were a great success during Scientific Sessions 2016 based on feedback from those attending the sessions. The summits focused on Arrhythmia Research, Stem Cells, Thrombosis and Vascular Disease. Additionally, the Precision Medicine Summit was held during Scientific Sessions. Read More
Reducing myocardial congestion has no effect on long-term heart failure survivalResults from the Trial of Ularitide’s Efficacy and Safety in Patients with Acute Heart Failure suggest that the standard model of AHF is incomplete. The trial found that vasodilation and the subsequent reduction of myocardial congestion improves heart failure outcomes during treatment but has no effect on long-term cardiovascular outcomes. Read More
Ticagrelor, clopidogrel show similar benefits for PAD patientsPatients who have peripheral artery disease will likely respond equally well whether treated with ticagrelor or clopidogrel as monotherapy, according to results from the Examining Use of Ticagrelor in PAD trial. Read More
Dec. 29
COX-2 inhibitor not inferior to naproxen, ibuprofen for CV riskConcern about the cardiovascular risks of cyclooxygenase-2 (COX-2) inhibitors may be overblown. The Prospective Randomized Evaluation of Celecoxib Integrated Safety versus Ibuprofen or Naproxen (PRECISION) trial showed that the COX-2 inhibitor celecoxib is not inferior to ibuprofen or naproxen in cardiovascular safety. Read More
HOPE-3: Lowering BP, cholesterol do not slow cognitive decline in elderlyHopes that lowering blood pressure or LDL cholesterol with medications might slow cognitive or functional decline in older people were tempered by the results of the Heart Outcomes Prevention Evaluation-3 (HOPE-3) trial. Read More